Loading...
•
Sep 30, 2025
Enanta Pharmaceuticals Q4 2025 Earnings Report
Enanta Pharmaceuticals reported a narrower net loss in Q4 2025 as revenue slightly increased year-over-year, driven by royalties from AbbVie’s HCV regimen.
Key Takeaways
Enanta Pharmaceuticals posted $15.1 million in revenue for Q4 2025, a marginal increase from the prior year. The company reduced its net loss to $18.7 million, reflecting lower R&D and administrative expenses.
Revenue rose to $15.1 million in Q4 2025, primarily from royalties on MAVYRET®/MAVIRET® sales.
Net loss narrowed to $18.7 million from $28.8 million in Q4 2024 due to reduced operating expenses.
Cash and cash equivalents stood at $188.9 million, expected to fund operations into fiscal 2029.
Announced new development candidates EPS-3903 and EDP-978 targeting immunological diseases.
Revenue by Segment
Forward Guidance
Enanta expects its cash position and ongoing royalties to sustain operations into fiscal 2029, with focus on advancing new immunology and RSV candidates.
Positive Outlook
- Cash and marketable securities of $188.9 million at fiscal year-end.
- Gross proceeds of $74.8 million from October 2025 public offering.
- EPS-3903 selected as lead STAT6 inhibitor development candidate.
- EDP-978 nominated as KIT inhibitor with IND planned in Q1 2026.
- Positive Phase 2b data for RSV candidate Zelicapavir in high-risk adults.
Challenges Ahead
- Q4 net loss of $18.7 million despite revenue increase.
- Ongoing royalty obligations to OMERS limit retained cash flow.
- Decrease in interest and investment income year-over-year.
- No progress reported on resolution of Pfizer patent litigation.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...